Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | AGMT MM 01: the oral microbiome as a predictor of PFS in R/R myeloma

Heinz Ludwig • 2 Jun 2020
EHA 2020
Multiple Myeloma Dexamethasone Ixazomib Thalidomide
AGMT MM 01

Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, discusses the AGMT MM 01 trial (NCT02410694), which investigated the oral microbiome in patients with relapsed/refractory multiple myeloma treated with ixazomib, thalidomide and dexamethasone. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Heinz Ludwig

2:50
Immunotherapy highlights at IMS 2023: bispecific antibodies, CAR-T cells & unanswered questions
Heinz Ludwig • 27 Sep 2023
2:02
Issues with CAR-T slot allocation in myeloma & the promise of locally manufactured products
Heinz Ludwig • 27 Sep 2023
3:49
Advances in technologies used to assess immune function in myeloma
Heinz Ludwig • 27 Sep 2023
2:59
Managing COVID-19 risks and exposures in patients with myeloma
Heinz Ludwig • 12 May 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals